An estimated 20 million people across the US, UK, and EU are taking GLP-1 receptor agonists like semaglutide and tirzepatide for type 2 diabetes and weight loss, driving a surge in reported side effects that includes hair loss. While high-quality randomized controlled trial data remains limited, survey data indicates that approximately 20% of patients using these medications experience hair shedding, creating enough concern that some individuals hesitate to begin treatment.
Two Distinct Forms of Hair Loss Linked to GLP-1 Use
Patients experiencing hair thinning while taking medications such as Ozempic or Mounjaro typically notice the onset within the first year of treatment, with shedding often peaking just before the 12th month. According to Lynn Petukhova, a geneticist at New York University who studies hair loss disorders, patients generally present with one of two distinct conditions.
The more frequent condition is telogen effluvium, a stress-related reaction where a physiological shock forces an unusually large percentage of hair follicles into a resting phase. These affected hairs stop growing and fall out two to three months later. Petukhova notes that this shedding is temporary and resolves once the underlying stressor stops, allowing normal hair growth to resume.
A smaller subset of patients experiences new or accelerated pattern baldness. In a recent study led by Petukhova, men taking GLP-1 medications faced a 7% higher likelihood of developing this genetically influenced hair loss compared to men not using the drugs. The study could not assess female risk due to less understood genetic markers in women. Manifestation varies by demographics, with white patients reporting higher rates of shedding and thinning, while Black patients more frequently report dryness and breakage.
Metabolic Stress and Genetic Risk Factors
Telogen effluvium during GLP-1 therapy stems primarily from rapid weight loss, driven by severe calorie restriction and subsequent micronutrient deficiencies caused by sharply reduced food intake. Higher doses of tirzepatide and semaglutide correlate with elevated rates of temporary hair loss. Women account for roughly 90% of reported telogen effluvium cases among GLP-1 users, mirroring the hormonal shifts seen postpartum or the shedding observed in up to 60% of patients following weight loss surgery.
Pattern baldness operates through a different biological mechanism. Petukhova explains that the medications likely unmask pre-existing genetic vulnerabilities, stating that individuals with a higher genetic predisposition see the trait triggered by the drug’s physiological impact.
Management Strategies and Medical Guidance
Patients considering GLP-1 therapy should discuss potential dermatological side effects with their healthcare provider beforehand. Because hair follicles depend heavily on proper nutrition, consuming adequate protein along with sufficient levels of iron, zinc, and biotin represents a prudent approach, though dietary precautions cannot guarantee the prevention of hair loss during rapid weight reduction. Opting for lower dosages and slower weight loss trajectories may also mitigate risk.
For individuals already experiencing shedding, dermatologists can help differentiate between temporary and permanent hair loss. Temporary telogen effluvium resolves with time and proper nutrition, whereas pattern hair loss may respond to treatments such as minoxidil or finasteride. Despite cosmetic concerns, Petukhova emphasizes that prioritizing metabolic health outweighs hair preservation for most patients, advising that getting metabolic health under control remains the primary clinical objective.